A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients
Publication
, Conference
Nand, S; Othus, M; Godwin, JE; Willman, CL; Norwood, T; Erba, HP; Howard, D; Coutre, SE; Appelbaum, FR
Published in: Blood
November 16, 2012
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 16, 2012
Volume
120
Issue
21
Start / End Page
3584 / 3584
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T., Erba, H. P., … Appelbaum, F. R. (2012). A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. In Blood (Vol. 120, pp. 3584–3584). American Society of Hematology. https://doi.org/10.1182/blood.v120.21.3584.3584
Nand, Sucha, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas Norwood, Harry Paul Erba, Dianna Howard, Steven E. Coutre, and Frederick R. Appelbaum. “A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients.” In Blood, 120:3584–3584. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.3584.3584.
Nand S, Othus M, Godwin JE, Willman CL, Norwood T, Erba HP, et al. A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. In: Blood. American Society of Hematology; 2012. p. 3584–3584.
Nand, Sucha, et al. “A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients.” Blood, vol. 120, no. 21, American Society of Hematology, 2012, pp. 3584–3584. Crossref, doi:10.1182/blood.v120.21.3584.3584.
Nand S, Othus M, Godwin JE, Willman CL, Norwood T, Erba HP, Howard D, Coutre SE, Appelbaum FR. A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. Blood. American Society of Hematology; 2012. p. 3584–3584.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 16, 2012
Volume
120
Issue
21
Start / End Page
3584 / 3584
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology